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Abstract
Here, we describe the generation of a novel type of HIV entry inhibitor using the recently developed Designed Ankyrin Repeat
Protein(DARPin)technology. DARPin proteinsspecific for human CD4 were selected froma DARPin DNA library usingribosome
display. Selected pool members interactedspecificallywithCD4 and competed withgp120for bindingtoCD4. DARPinproteins
derived in the initial selection series inhibited HIV in a dose-dependent manner, but showed a relatively high variability in their
capacity to block replication of patient isolates on primary CD4 T cells. In consequence, a second series of CD4-specific DARPins
with improved affinity for CD4 was generated. These 2nd series DARPins potently inhibit infection of genetically divergent
(subtype B and C) HIV isolates in the low nanomolar range, independent of coreceptor usage. Importantly, the actions of the
CD4bindingDARPinswerehighlyspecific:noeffectoncellviabilityoractivation,CD4memorycellfunction,orinterferencewith
CD4-independent virus entry was observed. These novel CD4 targeting molecules described here combine the unique
characteristics of DARPins—high physical stability, specificity and low production costs—with the capacity to potently block
HIV entry, rendering them promising candidates for microbicide development.
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Introduction
The increasing need for a vaccine to control the HIV pandemic is
undoubted, but recent failures of vaccine programs have made clear
that it will be years to decades before a successful vaccination
program can be installed [1]. In the meantime, drug based
intervention strategies must be found to fill the gap and put the
continuous spread of HIV at halt, particularly in resource poor
settings where 90% of the estimated 33 million HIV infected
individuals live [2].
HIV infection is predominantly acquired via heterosexual
transmission across mucosal surfaces [3]. Strategies that prevent
mucosal transmission are therefore considered to significantly impact
on diminishing viral spread [4]. Microbicides, agents that by topical
application on mucosal surfaces protect from HIV infection, are
regarded as one of the most promising preventive intervention
strategies in the absence of effective vaccination programs [2,4,5].
The sought for microbicides against HIV have to fulfill highly specific
requirements: Besides promoting strong and reliable protection from
HIV infection, these compounds have to be inexpensive, readily
available, stable, well tolerated and easy to apply to allow a wide
spread use. Recent efforts in microbicide research have mainly
focused on chemical compounds of relatively simplecomposition that
provide protection from HIV infection by largely nonspecific (non
HIV specific) mechanisms as for instance charge-charge interactions
[6]. Although in vivo efficacy of two such candidate microbicides,
nonoxynol-9 [7] and cellulose sulfate [8], could not be established [9–
12] several other pan-reactive molecules are in development that
show promise [4,6,13]. As for all drug interventions against HIV,
combination therapy will likely also be necessary in microbicide
application to reach potent and broad efficacy. Thus microbicides
that target HIV specifically and potentially can be used in
combination with pan-reactive molecules are urgently sought for.
Prime targets for microbicide attack are the virus and cellular
proteins involved in the early events in infection: the entry
receptors CD4, CCR5 and CXCR4, the viral envelope proteins
and compounds that interfere post entry with reverse transcription
and integration of HIV into the host cell. Application of specific
HIV inhibitors targeting these events as topical microbicides has
proven effective in blocking mucosal HIV transmission in the
SHIV macaque infection model underlining their potential in HIV
prevention [4,14–18].
PLoS Pathogens | www.plospathogens.org 1 July 2008 | Volume 4 | Issue 7 | e1000109To date only few small molecules that inhibit HIV entry have
been defined [4]. While protein-based inhibitors are commonly
more expensive in production, they can have functional
advantages. Most importantly, they provide outstanding target
specificity since the contact area between agent and target protein
is formed by comparatively large surface patches as for instance in
antibody-antigen interactions.
The aim of our study was to derive inhibitors of HIV entry that
achieve the desired specificity and potency together with the high
physical stability and low production costs required for the
application as microbicide. To this end, we made use of the
recently established Designed Ankyrin Repeat Protein (DARPin)
technology which is based on the principle of naturally occurring
ankyrin repeat proteins, a ubiquitously expressed family of
proteins mediating specific protein-protein interactions across
species [19]. DARPins were designed as an alternative to
antibodies: they share the antibodies’ ability to be selected and
to bind any given target with high affinity and specificity but are
clearly superior in terms of physical stability and production costs
[20,21]. Highly diverse DARPin DNA libraries, comprising at
least 10
11 different sequences per reaction, have successfully been
employed to identify enzyme inhibitors and specific binding
proteins in diverse biological systems [22–29].
The specificity and high affinity achieved in DARPin-target
interactions, paired with the fact that the 12 to 19 kDa DARPin
proteins have a remarkable physical stability and are expressed in
prokaryotic systems, allowing large scale production at relatively
low costs, renders DARPins promising candidates for the selection
of HIV inhibitors. Here, we report the successful selection and
characterization of CD4-specific DARPins and their function as
broadly active inhibitors of HIV entry, which underlines the
potential of this novel type of inhibitor molecules in HIV infection.
Methods
Ribosome display and selection for binders with
improved affinities
An introduction into the DARPin technology and ribosome
display is provided as Supporting Information (Protocol S1 and
Figures S1 and S2). Detailed specifics on the use and generation of
DARPin libraries has been described previously [20]. Here, N2C
and N3C libraries encoding for DARPins consisting of an N- and a
C-terminal capping repeat, and either two (N2C) or three (N3C)
internal ankyrin repeat modules containing randomized amino acid
residues, were used. The theoretical diversity of the N3C library is
3.8610
23. Ligated library DNA used in the selection described here
encoded for a minimum of 10
11 individual members [20]. The
diversity of the library is further increased by introducing errors
through the polymerase used in subsequent PCR cycles. Library
selections were performed against the tetrameric CD4 fusion protein
CD4-IgG2 (kindly provided by Bill Olson, Progenics Pharmaceuti-
cals; [30]) which was immobilized via a Fab-specific anti human
IgG-antibody (Sigma). For selections, PCR-amplified libraries were
transcribed and three standard ribosome-display selection rounds
were performed as described [23,31,32]. Two alternate approaches
were probed in the fourth selection round to achieve highly specific
binders: i) a standard ribosome display selection round with more
extensive washing(3 hintotal)and ii)theuseofpurifiedgp120ofthe
R5-tropic virus JR-FL (1 mM; kindly provided by W. Olson
Progenics Pharmaceuticals) to elute binders that compete with viral
glycoprotein for binding to CD4. The RT-PCR products of the
genes obtained after both fourth cycles were combined in a pool
(termed 1
st series binders) and then used for a single clone analysis as
described below.
In a separate line of experiments we aimed to select binders with
improved affinities for CD4. To this end, all round 3 and round 4
sublibraries were transcribed and translated in vitro as described
[33]. Then the ternary complexes of ribosome, mRNA, and
displayed proteins were equilibrated with 1 nM biotinylated CD4-
IgG2 at 4uC for 1 h before 1 mM non-biotinylated CD4-IgG2 was
added. The aliquots were incubated for 3 h at 4uC and the
complexes were recovered by binding to streptavidin-coated
magnetic beads (Roche Applied Science) for 30 min. The beads
were washed five times, and the RNA was eluted and purified as
described [33]. The pool of binders derived from this affinity
selection was termed 2
nd series binders and characterized as
described below.
Detection of selected binders by ELISA
CD4-IgG2 was immobilized via a Fab-specific anti-IgG capture
antibody (Sigma) on Maxisorp 96-well plates (Nunc). To screen for
CD4 binders, 100 mle a c ho fc r u d eEscherichia coli extracts containing
DARPins or purified DARPins were applied to wells containing
immobilizedCD4-IgG2 andtowellscontainingthecaptureantibody
alone. Bound DARPins were detected upon incubation with anti-
RGS-His antibody (Qiagen), anti-mouse-IgG-alkaline phosphatase
conjugate (Sigma) and p-nitrophenylphosphate (Sigma) as substrate.
Wells without CD4-IgG2 were used as negative controls to verify the
binding specificity of the tested DARPins.
Competition ELISA
For the gp120 competition ELISA the same setup as described
above was employed. CD4-IgG2 coated plates were incubated with
JR-FL gp120 (0–800 nM; kindly provided by Progenics Pharma-
ceuticals) for 1 h at 25uC before pure DARPins (200 nM) were
added. Detection and readout was carried out as described above.
For the competition ELISA using CD4-directed monoclonal
antibodies (mAbs) as competitors, soluble CD4 (20 nM, Progenics
Pharmaceuticals) was biotinylated using EZ-link sulfo-NHS-LC-
biotin (Pierce) according to the manufacturer’s instructions and
immobilized via neutravidin (Pierce, 66 nM) on Maxisorp 96-well
plates (Nunc). mAbs L222, Q4120, 13B82 [34,35] and 5A8 [36]
were kindly provided by Q. Sattentau. DARPin (20 nM) plus
different CD4-antibodies (66 nM) were added and incubated at
Author Summary
There is an increasing need to develop inhibitors of HIV
entry into target cells for both application in therapy and
prevention. The development of specific HIV inhibitors as
microbicides, agents that by topical application prevent
infection, is considered particularly important in limiting
the spread of HIV in the absence of effective vaccines. To
derive highly potent and specific inhibitors of HIV entry for
potential use as microbicide, we employed the recently
developed Designed Ankyrin Repeat Protein technology.
Using this technique, Designed Ankyrin Repeat Proteins
can be evolved that bind their target molecules as
specifically and efficiently as antibodies. In the present
study, we generated a panel of Designed Ankyrin Repeat
Proteins that bind specifically to the cellular CD4 receptor,
the main entry receptor of HIV. The obtained proteins are
very potent and highly specific inhibitors of HIV entry and
provide a broad reactivity against genetically different
virus strains. Due to the high physical stability of Designed
Ankyrin Repeat Proteins and their low cost production,
these novel HIV entry inhibitors represent promising
candidates for microbicide development.
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anti-poly-His-alkaline phosphatase conjugate (Sigma) as described
above. Wells without added antibody where included as control
and defined as 0% competition. Competition was rated as follows:
2, +, ++, and +++ for signal decreases of 0–25%, 25–50%, 50–
75% and 75–100%, respectively.
Protein purification and endotoxin removal
DARPins were produced in soluble form in E. coli and purified
using Ni-NTA affinity chromatography as described [37].
Endotoxins (lipopolysaccharides) were removed using 0.1% Triton
X-114 as described [38] and the DARPins were further purified
using EndoTrap red columns (Profos) according to the manufac-
turer’s recommendations. The remaining endotoxin content was
determined using the kinetic chromogenic limulus amebocyte
lysate assay (Endotell) according to the manufacturer’s instruc-
tions. All DARPin preparations used for investigation of cellular
activation had endotoxin levels below 0.5 EU/mg.
Surface plasmon resonance (SPR)
All SPR measurements were performed at 25uC using a Biacore
3000 instrument and a SA sensor chip (Biacore). To immobilize
CD4-IgG2, the protein was first chemically biotinylated using EZ-
Link sulfo-NHS-LC-biotin (Pierce). The individual DARPins were
applied in various concentrations (0.25–1’000 nM, depending on
affinity) to a flow-cell with immobilized CD4-IgG2 for 180 s at
50 ml/min, followed by washing with buffer. The signal of an
uncoated reference cell was subtracted from the measurements.
The kinetic data of the interactions were evaluated with a global fit
using the BIAevaluation 3.0 software (Biacore).
Generation of human mouse CD4 domain 1 chimera
A chimeric construct coding for human CD4, where the human
domain 1 sequence is replaced by its murine homologue sequence,
was constructed as follows: in pEYFP-N1-hCD4 (a kind gift from
Jun-ichi Fujisawa [39]), an expression vector for human CD4, a ScaI
restriction site was introduced at position 10 in CD4-domain 1 by
two conservative nucleotide exchanges via site directed mutagenesis
(QuikChange XL, Stratagene), resulting in plasmid pEYFP-N1-
hcD4-Sca. The murine CD4-D1 domain was amplified by PCR
from the plasmid pCMV-Sport6-mCD4 with primers mD1_fw:
gtcactcaagggaagacgctagtactggggaaggaaggg and mD1_rev:
ggtcaggctctgcccctgcagcaggtgggtacccggactgaagg. The PCR product
and pEYFP-N1-hCD4-Sca, which harbour unique ScaI and AarI
restriction sites, were digested with these two enzymes and the PCR-
derived insert encoding the murine CD4-domain 1 was ligated into
the human CD4 plasmid finally resulting in pEYFP-N1-hCD4mD1.
Immunofluorescent staining and analysis
Cells (100’000/well) were incubated with DARPins (200 nM)
for 20 min at 25uC. Bound DARPin was detected using anti-RGS-
His antibody (Qiagen) and goat-anti-mouse phycoerythrin labeled
antibody (Caltag). Binding of DARPins to CD4
+ A3.01 cells,
CD4
2 A2.01 cells (NIH AIDS Research & Reference Reagent
Program, No. 2059 and 166), CEM5.25luc.gfp (CD4
+; provided
by N. Landau) and TZM-bl cells (CD4
+; [40]) was investigated.
Cells were washed three times between all incubation steps using
PBS containing 0.1% azide and 1% BSA. After the last step, cells
were fixed (in PBS, 0.1% azide, 1.25% formaldehyde) and
subjected to flow cytometry using a FACSCalibur flow cytometer
(BD Biosciences) and Flowjo software (Tree Star).
To measure the effect of DARPin on cellular CD4 expression,
untouched CD4
+ T cells were isolated from CD8-depleted
peripheral blood mononuclear cells (PBMC) of healthy donors
using the CD4
+ T cell isolation kit II (Miltenyi Biotech) according
to the manufacturer’s instructions. Purity of the isolated CD4
+ T
cells was routinely .97%. CD4
+ T cells were cultured in the
presence or absence of the indicated DARPins at 200 nM for 1 h,
3 h, or 18 h. Thereafter, CD4
+ T cells were washed twice, stained
with PE-labeled anti-CD4 (Caltag) and analyzed for CD4
expression by flow cytometry.
To analyze overlapping binding patterns amongst the selected
CD4 specific DARPins, competition of DARPins to bind to
cellular CD4 was investigated. To this end, DARPins 29.2 and
57.2 were chemically modified with the HLX633 fluorescent dye
(Invitrogen) according to the manufacturer’s recommendations
and purified by size exclusion using NAP5 columns (GE
Healthcare). CD4
+ A3.01 cells were incubated with the fluores-
cently labeled DARPins at 20 nM (109,2 5 uC) followed by addition
of the unlabeled DARPins (1 mM, 209,2 5 uC). Cells were washed
thereafter and analyzed by flow cytometry.
To define the domain-specificity of selected DARPins, 293T
cells were transiently transfected with plasmids pEYFP-N1-hCD4
(see above), pCMV-Sport6-mCD4 (obtained from RZPD) or the
newly created chimeric construct pEYFP-N1-hCD4mD1 (see
above) with 25 kD polyethylenimine (Polysciences) as described
[41] and stained 48 h post transfection with fluorescently labeled
DARPins at a concentration of 5 to 50 nM and subsequently
analyzed by flow cytomtery.
Stimulated primary CD8-depleted PBMC
CD8
+ T-cell depleted (Rosette Sep cocktail, StemCell Technol-
ogies Inc.) PBMC were isolated by Ficoll-Hypaque centrifugation
of buffy coats obtained from three healthy blood donors. Cells
were adjusted to 4610
6/ml in culture medium (RPMI 1640
medium, 10% fetal calf serum, 10 U/ml interleukin-2, glutamine,
and antibiotics), divided into three parts, and stimulated with
5 mg/ml phytohemagglutinin (Sigma), 0.5 mg/ml phytohemagglu-
tinin, or anti-CD3 mAb OKT3 as previously described [42]. After
72 h, cells from all three stimulations were combined (referred to
as three-way-stimulated PBMC) and used as a source of stimulated
CD4
+ T cells for infection and virus isolation experiments.
Replication competent viruses
Replication competent viruses were produced by infection of
three-way stimulated PBMC. The 50% tissue culture infectious
dose (TCID50) was determined by end point dilution. Infections
were detected by p24 ELISA. In sum 10 subtype B viruses,
including 7 R5 users (JR-FL, SF-162, Pat 17, Pat 020, Pat 111, Pat
114, Pat 120) and 3 X4 users (NL4-3, 2044 and Pat 19) were
probed. Pat 17 is a R5 tropic primary isolate derived from plasma
of a chronically HIV infected individual as described [43]. The
origin of the other viruses has been described previously [42,43].
Env-pseudotyped HIV
Env-pseudotyped HIV was generated by transfection of 293T
cells with plasmids encoding the reporter gene expressing virus
backbone, pNLluc [44] (kindly provided by A. Marozsan and J. P.
Moore) and the respective functional envelope clone using 25 kD
polyethylenimine as described [41]. Viral supernatants were
harvested 2 days post transfection and the TCID50 was
determined by end point dilution. Infections were measured by
firefly luciferase activity (Bright-Glo Luciferase Assay System,
Promega). Plasmids encoding envelopes of R5 using viruses of
subtype B (AC10.0.29, PVO.4, QHO692.42, REJO4541.67,
RHPA4259.7, SC422661.8, TRJO4551.58, TRO.11,
WITO4160.33) and subtype C (DU123.4, DU151.2, DU156.2,
DARPins as Specific HIV Entry Inhibitors
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Plasmids encoding envelopes of JR-FL and NL4-3 were provided
by N. Landau and the plasmid encoding the envelope of SF162
was provided by L. Stamatatos.
Neutralization assays using env-pseudotyped virions on
TZM-bl cells
Neutralization assays on TZM-bl cells using pseudotype viruses
were performed as described [40]. Briefly, TZM-bl cells (10’000/
well; 96well format) were preincubated for 1 h at 37uC with serial
dilutions of DARPins and were then infected with aliquots of the
viruses (100 TCID50) together with DEAE dextran (10 mg/ml) in a
total infection volume of 200 ml. After three days, the cells were
lysed using Glo lysis buffer (Promega) and luciferase activity
determined upon addition of Glo substrate (Promega) on a Dynex
Technologies Luminometer. The DARPin concentration causing
50, 70, 90% reduction in luciferase reporter gene production after
48 h was determined by regression analysis.
Potential synergistic effects of combinations of the CD4-specific
DARPin 25.2 with other entry inhibitors were investigated with
JR-FL pseudotyped virus on the TZM-bl reporter cell line.
Combination indices [CI] were calculated using the Loewe
additivity formula [47–49]:
DAA B j I ðÞ
DA I ðÞ
z
DBA B j I ðÞ
DB I ðÞ
~CIAB I ðÞ
DA (I) is the dose of drug A alone required to result in inhibition I
and DA|AB (I) the dose of drug A in the combination of A+B
required to give the inhibition I. CI of 1 indicates additivity, ,1
synergy and .1 antagonism.
PBMC based neutralization assay
Inhibition of replication-competent virus infection of primary
human CD4 T cells was assessed essentially as described [50].
Briefly, stimulated CD8 depleted PBMC (100’000/well) were
preincubated for 1 h with DARPins at 37uC, followed by infection
with the respective replication-competent virus (100 TCID50). After
incubation for 6 to 8 days, p24 antigen production was determined
in cellular supernatant by ELISA as described [49,51]. The DARPin
concentration causing 70% reduction inp24 antigen production was
determined by regression analysis as described [42].
For macaque PBMC based neutralization assays, macaque
PBMC were cultured with 5 mg/ml of PHA-P (Sigma) for 3 days,
before being plated at 2610
5 cells per well of a 96 well plate
(Becton Dickinson) in medium with 50 U/ml IL-2. Graded doses
of the CD4-specific DARPin 25.2 or the control E3_5 DARPin
were added to each well (duplicates per dose) and incubated for
1 h at 37uC. After the incubation, 1000 TCID50 of SIVmac239
was added to each well (with 50 U/ml IL-2). The cells were
cultured for 7 days (adding more IL-2 every other day), after which
the cells were collected and lysed for PCR. SIV infection was
measured using a Q-PCR assay for SIV gag DNA [52,53]. The
DARPin concentration causing 90% reduction in SIV gag DNA
was determined by regression analysis.
Effects of DARPins on dendritic cells (DC)
Monocytes were isolated from PBMC by positive selection with
CD14 microbeads (Miltenyi). Purified monocytes were cultured
for 4 days in RPMI-10% FCS containing 1000 U/ml GM-CSF
and 1’000 U/ml IL-4 (both from Immunotools). Monocyte-
derived DC were then washed twice, seeded at 1610
6/ml and
treated with the purified DARPin preparations (375 nM) for 24 h.
E. coli lipopolysaccharide (2.5 EU/ml; Charles River Endosafe)
was used as control. Finally, to assess the activation status of the
cells, DC were stained with PE-labeled anti-CD80 (BD Bioscienc-
es) and with propidium iodide (BD PharMingen) and CD80
expression levels were quantified by flow cytometry.
Assessment of T cell proliferation
Labeling of PBMC with CFSE (carboxy-fluorescein succinimi-
dyl ester) was performed as described [54]. Briefly, CD8-depleted
PBMC from a single donor were stained 8 min at room
temperature with 3 mM CFSE (Molecular Probes). Staining was
stopped by addition of an equal amount of FCS and cells washed
three times with PBS containing 1% FCS. CFSE-labeled cells were
incubated with 500 nM endotoxin purified DARPin (1 h at 37uC)
and cultured for 4 days in RPMI 1640 containing 10% FCS,
antibiotics, 100 U/ml interleukin-2 and anti-CD3 mAb OKT3.
The cells were analyzed by flow cytometry using anti-CD3-PE and
propidium iodide for gating. Proliferation of cells was assessed on
the basis of the shifts in the CFSE- labeling intensity using the
FlowJo software as described [54].
Assessment of T helper memory cell function in presence
of CD4 specific DARPin
To assess whether CD4-specific DARPins interfere with T
helper memory cell functions, activation of antigen-specific T cells
in presence and absence of DARPin 55.2 and the control E3_5
using a standard interferon-c ELISpot assay was assessed [55].
Briefly, 96-well membrane plates (MAIP S45, Millipore) were
coated overnight with anti-human IFN-c antibody (1-D1K,
MAbtech). CD8-depleted PBMC were isolated one day prior to
the experiment and cultured in RPMI 1640 containing 10% FCS
and antibiotics overnight. The next day cells were preincubated
with 200 nM (streptokinase/streptodornase experiment) or
250 nM (cytomegalovirus experiment) endotoxin free DARPins
55.2 and E3_5 for 1 h at 37uC. Cells (2610
5) were then seeded
into wells of the coated 96-well membrane plates and stimulated
with either streptokinase/streptodornase (400 U/ml) or cytomeg-
alovirus (CMV)-lysate (10 mg/ml) overnight at 37uC. Phytohaem-
agglutinin (10 mg/ml) was used as positive control. IFN-c
production was detected by sequential addition of a detection
antibody cocktail containing a biotinylated anti-human IFN-c
antibody (7-B6-1, MAbtech), streptavidin alkaline phosphatase
(MAbtech), followed by washing. AP (alkaline phosphatase)
conjugate substrate kit (Biorad) was used and the resulting colored
spots were quantified using an ELISpot reader (AID). Background
reactivity observed in cultures without stimulation was subtracted
and results are expressed as specific spot forming cells (SFC) per
10
6 CD8-depleted PBMC.
Interference of DARPins with CD4:MHC class II interaction
To study if CD4 specific DARPins interfere with CD4:MHC
class II interaction directly, we performed a cell based binding
assay based on rosette formation between CD4 and MHC class II
expressing cells [56]. Briefly COS-7 cells (ATTC CRL-1651;
cultivated in DMEM, 10% FCS) were seeded at a density of
200’000 cells per 6-well, and one day later transfected with the
CD4 encoding plasmid pEYFP-N1-hCD4 ([39]) using the Ca-
phosphate transfection system (Promega) according to the
manufacturer’s instructions. Transfection medium was replaced
8 h later and two days post transfection cells were utilized in the
rosette assay. To this end CD4 expressing and control COS-7 cells
were treated with CD4 specific DARPins (23.2, 25.2, 27.2, 29.2,
55.2, 57.2), and a control DARPin (E3_5), buffer or the anti-CD4
DARPins as Specific HIV Entry Inhibitors
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known to block CD4 binding to MHC II, for 30 min at 37uCa ta
concentration of 50 nM or 200 nM. Subsequently, medium was
removed, and cells incubated with 1610
7/well Raji B cells (NIH
AIDS Research & Reference Reagent Program, No. 9944)
cultivated in RPMI1640, 10% FCS) containing identical concen-
trations of inhibitors. After 1 h incubation at 37uC non-adherent
cells were removed by washing the wells gently seven times with
medium. Cells were then fixed with 1.5% paraformaldehyde (PFA)
and rosette formation assessed microscopically.
Crossreactivity with macaque CD4
Crossreactivity with rhesus CD4 was investigated using PBMC
from adult male and female chinese rhesus macaques (Macaca
mulatta) which were housed at the Tulane National Primate
Research Center (TNPRC; Covington, USA). Animals were
anesthetized with ketamine-HCl (10 mg/kg) prior to heparinized
blood samples being taken (no more than 10 ml/kg/month/
animal). Protocols were reviewed and approved by the Institu-
tional Animal Care and Use Committee of the TNPRC. Animal
care procedures were in compliance with the regulations detailed
in the Animal Welfare Act and in the ‘‘Guide for the Care and Use
of Laboratory Animals’’. PBMC were isolated using Ficoll-
Hypaque density gradient centrifugation (GE Healthcare). Cells
were washed twice in 16 PBS and resuspended in FACS wash
(FW) buffer (16 PBS supplemented with 1% human serum and
1 mM EDTA, both from Sigma). For DARPin staining, 4610
5
macaque PBMC were resuspended in 50 ml FW buffer in a 96 well
plate (BD Biosciences). DARPins, 2 ml of each (5 mM), were added
to the cells and incubated for 20 min at 4uC. Cells were washed
twice in FW buffer and CD4 T cells were identified using a 1/25
dilution of FITC-conjugated anti-CD3 (clone Sp34, BD PharMin-
gen) and PE-conjugated anti-CD4 (clone L200, BD PharMingen).
PE- and FITC-conjugated isotype Ig controls were included in all
experiments and typically gave signals ,1 log of fluorescence. To
detect DARPin binding, cells were incubated with a 1/100
dilution of the anti-Penta-His Alexa Fluor 647 conjugate (Qiagen).
The DARPin negative control was no DARPin with anti-Penta-
His Alexa Fluor 647. Gates were set to include all mononuclear
leukocytes based on the forward- and side-scatter characteristics
(excluding any contaminating neutrophils). The gates used to
define the CD3/CD4 cells were determined based on the isotype
controls. All samples were acquired on a FACSCalibur (BD
Biosciences) and analyzed using FlowJo software (Tree Star, Inc).
Mean fluorescent intensities (MFI) of DARPin staining in the
CD3/CD4 population were adjusted by subtracting the MFI of
the negative DARPin control. Standard deviations represent n=4
animals, processed and stained in parallel.
Results
Selection and biochemical characterization of CD4-
specific DARPins
DARPins specific for human CD4 were selected using N2C and
N3C DARPin libraries, which harbor two and three randomized
ankyrin repeats, respectively. Specific DARPins were isolated from
these libraries by performing ribosome-display selection rounds
[31,32] against the tetrameric CD4-immunoglobulin molecule,
CD4-IgG2, expressing domains D1 (encompassing the binding site
for the HIV envelope protein gp120; [57]) and D2 of human CD4
[30]. Although an enrichment of binders was observed already
after the second ribosome-display selection round (data not
shown), four selection rounds were performed to increase
specificity before the selected library members were further
analyzed. This pool of DARPins obtained after four rounds
(referred to as 1
st series pool) was screened for CD4 specificity
directly from crude bacterial lysates by ELISA (Figure 1A). More
than 50% of the examined candidate DARPins showed specific
binding (signal/background $2), whereas unselected DARPins
showed no interaction with immobilized CD4-IgG2 (data not
shown). Out of this pool of CD4-specific DARPins, six candidate
proteins with the most favorable binding properties in the ELISA
screen were chosen (referred to as 1
st series binders) and purified to
homogeneity for further investigations. The six selected proteins
were purified and their capacity to bind to CD4 in presence and
absence of gp120 assessed (Figure 1B). Notably, all six selected
DARPins interfered with gp120 binding to CD4. We further
analyzed the ability of DARPins to interact with the native CD4
receptor ina cellularcontext. Allprobed selected DARPins bound to
CD4
+ cell lines and to primary CD4
+ T cells but not to CD4
2 cell
lines,whereastheunselectedcontrolDARPin,E3_5,didnot interact
with any of the tested cell lines (Figure 1C and data not shown).
As affinity and kinetics of the interaction with CD4 are
anticipated to steer the efficacy of the DARPins as inhibitors of
HIV entry, we investigated the interaction of one candidate from
the 1
st series pool, DARPin 3.1, with CD4 by kinetic SPR
measurements. Association and dissociation experiments at
various concentrations of DARPin 3.1 with immobilized CD4-
IgG2 yielded a dissociation constant (KD value) of 8.9 nM, which is
in the range of high affinity antibodies (Table 1).
CD4-specific DARPins are potent HIV entry inhibitors
To explore the effect of CD4-specific DARPins on HIV entry
we evaluated the inhibitory activity of our panel of CD4-DARPins
in vitro using a standardized assay system based on infection of
TZM-bl reporter cells with envelope pseudotyped HIV particles
[58]. All tested DARPins inhibited HIV entry of JR-FL, SF-162
and NL4-3 env-pseudotype viruses in a dose-dependent manner
with IC50 values ranging from 67.8 nM to 820 nM (Supporting
Table S1). Importantly, none of the CD4-selected DARPins had
an effect on CD4-independent virus entry as demonstrated by
their inability to block entry of murine leukemia virus (data not
shown). Equally, an unselected DARPin (E3_5) had no effect on
HIV entry (Figure 2B and data not shown).
When we further explored the effects of the DARPins against a
panel of 10 replication-competent R5 or X4 virus isolates of
subtype B on primary lymphocytes (Figure 2A) we confirmed that
all selected DARPins inhibited replication of the tested virus
isolates, even over multiple rounds of replication. Notably though,
we observed a considerable variability in the sensitivity of different
viruses with IC70 values ranging from ,24 nM up to .1 mM,
with a relatively high resistance of the three probed X4 isolates to
the DARPin inhibitors.
Selection for improved affinities results in higher
inhibition potencies
This relatively high variability in suppressing virus replication
on primary CD4
+ T cells suggested that DARPins with superior
activity are needed to achieve potent and broad inhibition of
genetically diverse isolates in vivo. We reasoned that increasing the
affinity of the DARPins to CD4 is the most feasible strategy to
boost their potency in inhibiting HIV entry. To enrich for
DARPins with high affinity for CD4 we performed off-rate
selections during ribosome display to specifically select for proteins
with low dissociation rates [59]. To that end, we combined the
DNA-sublibraries generated during the first selection rounds and
performed a single round of off-rate selection where dissociation of
DARPins with low affinity was induced by addition of excess CD4
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PLoS Pathogens | www.plospathogens.org 5 July 2008 | Volume 4 | Issue 7 | e1000109Figure 1. DARPins interact specifically with CD4 and compete with gp120 for binding to CD4. (A) Binding of DARPins, in the form of
crude bacterial lysates, to CD4-IgG2 (black) is determined by ELISA and compared with binding to the capture antibody alone (gray). DARPins A–F
show specific binding to CD4-IgG2, a property that was confirmed by further tests using the purified proteins. DARPins G and H reveal nonspecific
binding whereas I and J are examples of library members that do not recognize the target protein. (B) Competition ELISA using soluble gp120 as
competing ligand. Shown is binding of 200 nM of the CD4-specific DARPins 1.1 to 6.1 in competition with 0 nM, 50 nM and 800 nM gp120. Binding
of DARPins alone was defined as 100% and background binding as 0%. (C) Binding of the DARPins to cellular CD4 was tested using A2.01 cells
(CD4
2), the CD4 expressing lines A3.01 cells, TZM-bl cells, CEM 5.25 cells and CD8-depleted PBMC as source of primary CD4 T cells. CD4-specific
DARPins D3.1 (blue), D23.2 (red), and of a control DARPin, E3_5 (black), an unselected library member binding to the various cell types are shown. PE-
labeled CD4-antibody (clone Q4120, Sigma) (green) was used as positive control and a PE-labeled goat-anti-mouse antibody (shaded in gray) as
negative control. The shifts in fluorescence intensity correspond to the differences in affinities of the DARPins for CD4 (see Supporting Table S1).
Representative data from 2–4 independent experiments are shown.
doi:10.1371/journal.ppat.1000109.g001
Table 1. Dissociation constants of CD4 specific DAPRins as determined by surface plasmon resonance (SPR).
Binder kon 1 [1/Ms]; kon 2[ 1 / s ] k off 1 [1/s]; koff 2[ 1 / s ] K D [M] fitting model Chi
2/Rmax
D3.1 9.43E+05 1.03E-01 8.93E-09 two state
1 2.26%
3.47E203 3.09E-04
kon [1/Ms] koff [1/s]
D23.2 2.96E+06 7.66E-04 2.59E-10 1:1
2 3.40%
D27.2 1.39E+06 2.44E-03 1.75E-09 1:1
2 0.48%
D29.2 1.11E+06 1.66E-03 1.49E-09 1:1
2 4.70%
D55.2 1.43E+06 1.20E-03 8.39E-10 1:1
2 1.64%
D57.2 1.39E+06 2.44E-03 1.75E-09 1:1
2 0.48%
1Data required use of the two state model, which assumes a conformational change upon binding, for fitting.
2Data gave best fits using the standard 1:1 langmuir binding model.
doi:10.1371/journal.ppat.1000109.t001
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DARPins, D23.2, D25.2, D27.2, D29.2, D55.2 and D57.2
(referred to as 2
nd series binders), for further analysis.
When we assessed this panel of 2
nd series binders using kinetic
SPR measurements we found that off-rate selection had indeed
resulted in selection of binders with dissociation constants (KD) that
were almost exclusively in the subnanomolar range (Table 1).
When compared to DARPin 3.1, the most potent inhibitor of the
1
st series, this represents a 5 to 10-fold decrease in KD values.
Importantly, this substantial increase in affinity was also reflected
by a dramatic increase in HIV entry inhibition potency of the 2
nd
series over the 1
st series binders (Figure 2B). The IC50 values of
the six affinity improved binders against the reference strains JR-
FL, SF162 and NL4-3 in the TZM-bl based assay were in the
range of 1.1 to 5.1 nM, 1.2 to 7.7 nM, and 2.7 to 10.5 nM,
respectively (Supporting Table S1). In sum, this represents about a
70-fold reduction in inhibitory concentrations (p,0.0001, un-
paired t test) over the 1
st series DARPin inhibitors and renders the
2
nd series inhibitors equal in potency to the clinically approved
entry inhibitor T-20 [60–62], which was probed alongside and
inhibited replication of JR-FL, SF-162 and NL4-3 pseudotyped
viruses with IC50 values of 1.1 nM, 3.1 nM and 8.1 nM,
respectively.
While the 1
st series DARPins displayed a relatively wide
variability in their potency to inhibit infection of PBMC by
replication-competent viruses (Figure 2A, Table S1), the 2
nd series
DARPins were significantly improved and blocked virus replica-
tion at IC70s in the very low nanomolar range (2.1 nM-30.9 nM;
Figure 2B and Table S1). The most potent inhibitors of this pool,
DARPins 55.2 and 57.2 blocked HIV replication of the three
probed viruses, JR-FL, SF-162 and NL4-3, with IC70 values
between 2.1 and 7.8 nM.
Potency and breadth of CD4-specific DARPins
To obtain more detailed information on potency and breadth of
the CD4-specific DARPins we analyzed the activity of DARPin
Figure 2. The selected CD4-specific DARPins potently inhibit HIV entry. (A) Effect of the six selected CD4-specific DARPins of the 1
st series
(D1.1–D6.1) on the entry of replication-competent viruses (7 R5 and 3 X4 users) on PBMC. 70% inhibitory concentrations (IC70) derived in
representative individual experiments are reported. (B) Inhibition of HIV entry by 1
st and 2
nd series DARPins: CD4-specific DARPins of the 2
nd series
(red to yellow) are more potent inhibitors of HIV entry as DARPins of the 1
st series (dark blue to light blue). Inhibition of JR-FL, SF-162 and NL4-3
infection in a pseudotyped virus entry assay on TZM-bl cells (upper panels) and the respective replication competent viruses in a PBMC based assay
(lower panels) was probed in parallel. The unselected DARPin E3_5 (gray) was used as control in the TZM-bl based assay. Data points are means of
virus replication measured in two replicate wells. See Supporting Table S1 for a summary of the derived IC50 and IC70 values in these assays.
doi:10.1371/journal.ppat.1000109.g002
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st series pool, and DARPin
55.2, as representative of the 2
nd series, against a reference panel
of nine subtype B and four subtype C env-pseudotyped R5 viruses
(Figure 3A). Notably, D3.1 only reached IC50 values between 20.2
and 144.8 nM (median: 67 nM) against clade B viruses and 11.3
to 52.5 nM (median: 28 nM) against clade C viruses while
DARPin 55.2 inhibited both subtype B and C viruses very
potently with IC50 values of 0.4–4.1 nM for subtype B (median:
1.3 nM) and 0.3–1.6 nM for subtype C viruses (median: 0.7 nM).
The latter confirmed the result of the initial screen and verified
that the 2
nd series DARPins have a markedly improved capacity to
inhibit HIV, irrespective of the genetic background of the virus.
As with all inhibitors against HIV, effective application of CD4-
specific DARPins for prevention or therapy will require their use
in combination with other types of inhibitors. To probe potential
effects of CD4-DARPins in drug cocktails, DARPin 25.2 was
tested for its efficacy in inhibiting HIV entry in combination with a
series of entry inhibitors: the neutralizing mAbs IgG-b12 [63], 2F5
[64], 4E10 [65] and 2G12 [66], the fusion inhibitor T-20 [60], the
anti-CCR5-mAb PRO140 [67] and CD4-IgG2 [30].
The results showed a clear pattern: DARPin 25.2 acted in
synergy (CI 70: 0.42–0.77, CI 90: 0.25–0.54) with all anti-cell and
anti-viral inhibitors with the exception of CD4-IgG2 for which -
consistent with the CD4-specificity of the DARPins - antagonism
was observed (CI 70: 2.31, CI 90: 2.05; Figure 3B and C). The
precise mechanisms by which blocking of CD4 promotes
synergistic effects in combination with anti-envelope targeting
inhibitors remain to be determined. Synergistic effects could, for
example, arise when thresholds of receptor levels required for
successful entry are not met. In summary, our data underline the
potential of CD4-specific DARPin inhibitors, as they promote
higher inhibitory activity in conjunction with entry inhibitors
directed to different targets.
Specificity of selected DARPins
To derive further information on their target specificity, we
studied binding of a selection of 2
nd series DARPins to CD4 in
competition with a panel of CD4-binding mAbs. In general, strong
competition with the three D1 binding mAbs (L222, Q4120,
13B82 [34,35]) was observed, while less interference was found
with 5A8 [36], a D2 binding antibody (Table 2). Notably, this
competition by mAb 5A8 was not observed with DARPin 23.2,
but with all other tested DARPins.
In summary these experiments suggest that the selected DARPins
have overlapping specificities mainly directed against D1. We
confirmed these experiments in competition experiments in which
binding of fluorescently labeled DARPin 29.2 or 57.2 to CD4
expressing cells was probed in presence of unlabeled competitor
DARPins(Figure 4A). Both sets ofexperiments gave identicalresults:
the labeled DARPin was competed off by all other CD4 specific but
not the control DARPin E3_5, indicating that the probed CD4-
specific DARPins have closely overlapping epitopes.
To more specifically define the binding domain of the DARPins
we generated a chimeric CD4 molecule in which domain 1 of
human CD4 was exchanged by the corresponding domain of
mouse CD4. The chimeric CD4 molecule expressed well upon
transfection in 293-T cells, and had the required specificities, as
antibody S3.5, specific for human D1, failed to bind, whereas mAb
GK1.5, specific for mouse D1, bound the chimeric molecule but
not wild type human CD4 (data not shown). Likewise mAb
OKT4, specific for human CD4 D3, bound equally well to both
wildtype human CD4 and the chimeric molecule (Figure 4B).
Binding studies with the CD4 specific DARPins revealed that
while all DARPins bound wildtype human CD4, they failed to
bind the chimeric mouse domain 1 molecule mirroring the
Figure 3. CD4-specific DARPins efficiently inhibit entry of both subtype B and C viruses. (A) Graphical representation of the IC50 values of
a1
st series DARPin, D3.1, and a 2
nd series DARPin, D55.2, tested using env-pseudotyped viruses of subtype B (n=9) and subtype C (n=4) on TZM-bl
cells. The following median IC50 values were determined: 45.4 nM for DARPin 3.1 (67.1 nM and 28.2 nM for clade B and C viruses, respectively) and
1.3 nM for DARPin 55.2 (1.3 nM and 0.7 nM for clade B and C viruses, respectively). (B) Inhibition curves of JR-FL pseudovirus used to assess synergy
by analyzing combination indices (CI) in Figure 3C. Equipotent stocks of inhibitors were used to obtain comparable inhibition curves. Inhibitory
effects of DARPin 25.2 (gray square) and the 2F5 mAb (gray triangle) alone are shown aside by side with the calculated (light gray, open triangle) and
the actual observed inhibitory effect (black circles) of a 1:1 mixture of the two inhibitor stocks. (C) DARPin 25.2 shows potent synergy in JR-FL
pseudovirus inhibition in combination with neutralizing mAbs or entry inhibitors. CI for the inhibitory concentrations 70% and 90% (CI70, CI90) are
represented for DARPin 25.2 in combination with mAbs IgG-b12, 2F5, 2G12, 4E10, the fusion inhibitor T-20, the anti-CCR5 mAb Pro140 and CD4-IgG2.
Means from three independent experiments are shown. Error bars indicate the standard error of the mean.
doi:10.1371/journal.ppat.1000109.g003
Table 2. Competition between DARPins and CD4-specific
antibodies for binding to CD4.
mAb/DARPin 2 E3_5 23.2 27.2 29.2 55.2 57.2
2 2 2 22222
5A8 22 2 ++ + ++
L222 22 +++ +++ +++ ++ ++
Q4120 22 +++ +++ +++ +++ ++
13B82 22 + ++ + ++ ++
a-Flag 2 2 22222
doi:10.1371/journal.ppat.1000109.t002
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for CD4 domain 1 (Figure 4B).
Probing the effect of CD4-specific DARPins on cell function
Since the action of CD4-specific DARPins is directed against the
host cell, particular care has to be taken to assess their effect on cell
function before these agents can be considered for further
development as HIV inhibitors. In a first step, we investigated
whether CD4-specific DARPins interfere with CD4 T cell
proliferation, by probing the effect of a candidate CD4-specific
DARPin (D55.2) and a nonspecific control DARPin (E3_5) on
primary CD4
+ T cell proliferation over a four day period. As
Figure 5A shows, addition of the CD4-binding DARPin had no
noticeable impact on cell proliferation compared to the untreated
control.
To explore the effects of CD4 engagement by DARPins on
dendritic cells (DC), we assessed whether treatment of immature
monocyte-derived DC with DARPin 55.2 for 24 h induced
activation and maturation of these cells, which is reflected by
increased expression of the costimulatory molecule CD80. Neither
the CD4-specific DARPin 55.2 nor the control DARPin induced
DC maturation (Figure 5B), whereas E. coli lipopolysaccharide
(LPS), known to induce DC maturation via TLR-4, gave rise to a
pronounced shift in CD80 expression (data not shown).
Notably, the DARPins did not reveal any cytotoxic effects:
prolonged incubation of primary cells with DARPin - CD4-
specific or unselected - did not result in increased cell death as
measured by uptake of propidium iodide: Both the CD3+ T cells
(incubated with DARPins, 500 nM, for 4 days) and the dendritic
cells (incubated with DARPins, 375 nM, for 24 h) remained
unaffected (Figure 5C).
Effect on CD4 receptor density
As our competition binding experiments with gp120 indicate
(Figure 1B), CD4-specific DARPins most likely act by blocking
viral attachment to the receptor. Theoretically, binding of the
DARPin to CD4 could also induce receptor internalization and
DARPins thus may exhibit their antiviral activity through
decreasing CD4 receptor density on the target cells. To probe
this, we explored the effect of DARPin binding on surface CD4
receptor levels of primary CD4 T cells. Treatment of CD4 T cells
from healthy donors with DARPin for 0, 1, 3 and 18 h at 37uC (to
Figure 4. Characterization of the binding domain of CD4 specific DARPins. (A) Competition between the fluorescently labeled DARPins
D29.2HLX and D57.2HLX with unlabeled DARPins was analyzed by flow cytometry using CD4
+ A3.01 cells. Compared to the control with no
competitor (shaded in gray) competitive binding was observed for all CD4-specific DARPins (E3_5: blue; D23.2: light blue; D25.2 red; D27.2: orange;
D29.2: brown; D55.2: green; D57.2: purple). The autofluorescence control is shown as dotted line (B) Binding of the same DARPins to human CD4
(hCD), murine CD4 (mCD4) and chimeric human CD4 containing murine D1 domain in the human CD4 context (hCD4mD1), indicating that all tested
DARPins bind to the D1 domain of human CD4. The same coloring scheme for DARPins as in Figure 4A was used. MAb OKT4, specific for human CD4-
D3, is shown as black dotted line.
doi:10.1371/journal.ppat.1000109.g004
Figure 5. Interaction of DARPins with CD4 has no detectable effect on cell viability and stimulation. (A) PBMC stimulation with IL-2 and
OKT3 to induce proliferation was not altered in presence of the CD4-specific DARPin 55.2 (red), the non-binding DARPin E3_5 (blue) or absence of
DARPin (gray) over a 4 day period. Proliferation was monitored by flow cytometry by determining CFSE dilution as a result of cell division. One
representative experiment out of two is shown. (B) Activation of dendritic cells (DC) as determined by CD80 expression. Neither addition of DARPin
55.2 (red), nor of control DARPin E3_5 (blue), resulted in detectable upregulation of CD80 on DC over a 24 h period. One out of two independent
experiments is depicted. (C) Prolonged treatment of T lymphocytes (4 days) and immature monocyte derived DC (24 h) with DARPin 55.2 (CD4
specific) and E3_5 (unselected control DARPin) has no effect on cell viability. Viability was determined by propidium iodide staining. DARPin
concentration in the lymphocytes and DC cultures were 500 nM and 375 nM, respectively. (D) Interaction of DARPins with CD4 does not result in
downregulation of surface CD4. Untouched peripheral blood CD4
+ T cells were cultured in presence or absence of the indicated DARPins for 1 h, 3 h
or 18 h at either 37uC (red line) or 4uC (blue line). Cells were stained for CD4 and the expression of surface CD4 was analyzed by flow cytometry.
Shown is one representative experiment out of four.
doi:10.1371/journal.ppat.1000109.g005
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yielded identical results: Neither treatment with the CD4 specific
nor the unspecific DARPin resulted in down- or upregulation of
CD4 (Figure 5D). Recognition of CD4 by the CD4 mAb used in
these FACS analyses was not impaired in the presence of CD4
specific DARPin. Most importantly, CD4 staining in presence of
CD4 specific DARPin remained stable independently whether
DARPin and mAb were added simultaneously or cells were
pretreated with DARPin for extended time periods (Figure 5D).
Effect of CD4 specific DARPins on CD4 interaction with
MHC class II
In the absence of T cell receptor interaction the binding of CD4
to MHC class II is of extremely low affinity (KD=200 mM; [68]).
Using a previously established assay that allows to study this weak
interaction based on rosette formation between CD4 and MHC-II
expressing cells [56], we were able to show that all tested
DARPins, 23.2, 25.2, 29.2, 55.2 and 57.2, as well as the CD4-D1
specific antibody Q4120 blocked rosette formation efficiently
(Figure 6A and data not shown). Hence, in the absence of cognate
T cell receptor (TCR) and peptide, the CD4 specific DARPins
interfered with CD4 binding to MHCII.
To probe the effect on specific T cell functions, we assessed if
the CD4-specific DARPin 55.2 affects activation of memory T
helper cells specific for either streptokinase/streptodornase or
cytomegalovirus antigens. When we quantified antigen specific
IFN-c producing cells that were stimulated in presence or absence
of 200 nM of D55.2 or the non-binding control DARPin E3_5 we
observed in both cases no inhibition of the T cell functions
(Figure 6B). This indicates that, at least for the CD4-specific
DARPin probed, even at high dosing of the molecule specific
memory T helper responses are activated.
Efficacy of DARPins in blocking rhesus macaque CD4
To evaluate the potential of using these binders directly in non-
human models, crossreactivity of the DARPins with CD4 from
rhesus macaques was investigated. The sequence identity between
human and macaque CD4 is 91% on the amino acid level, as
opposed to 54% between human and murine CD4. Experiments
using PBMC from macaques revealed that 4 out of 7 tested
DARPins recognize also rhesus CD4 (Figure 7A), while none of
them interacts with murine CD4 (data not shown and Figure 4B).
This finding is intriguing as it opens the possibility to probe the
potential of DARPins as candidate microbicides in the macaque
infection model. To obtain an initial insight into the potential of
these DARPins in inhibiting SIV infection, we probed the efficacy
of DARPin 25.2 in blocking SIVmac239 infection of primary
rhesus macaque cells. Results obtained in infection experiments
with cells from three individual donors depicted in Figure 7B
indicate that DARPin 25.2 potently inhibit SIV infection of these
cells.
Discussion
Making use of the recently developed DARPin technology [19–
21,23], we investigated here DARPins as HIV-specific inhibitors
since they can be engineered to fulfill many of the sought for
properties of a microbicide, namely high target specificity and
affinity, high physical stability and comparatively low production
costs. As proof of concept, we aimed to derive DARPin-based
inhibitors that target CD4, the primary receptor for HIV. The
technology employs highly diverse DARPin DNA libraries
combined with ribosome display as selection technology, which
allowed the selection of binders with specificity for the CD4
receptor in a relatively short time. The resulting DARPins
interacted with very high affinity with human CD4 as reflected
by dissociation constants in the lower nanomolar range, which
upon off-rate selection even reached subnanomolar values. This
high affinity has proven a common characteristic of DARPins:
although monovalent binders, they routinely achieve affinities that
are equal if not superior to most antibodies [23,26,28,59]. We
subjected the derived CD4-specific DARPins to a careful
assessment of the HIV inhibitory capacity. Notably, all probed
CD4-specific DARPins from the 1
st and the 2
nd, affinity improved
series inhibited HIV entry both in cell line and primary cell based
infection systems. Inhibition was achieved over both single round
and multiple rounds of infection proving the stability of this effect.
Particularly notable was the potency of the 2
nd series DARPins,
which were specifically selected for low dissociation rates. They
exhibited potent and broad neutralization of HIV across subtypes
Figure 6. Effect of DARPin on T cell function and MHC class II interaction. (A) The effect of the DARPin:CD4 interaction was assessed in a
binding assay based on rosette formation between CD4 and MHC class II expressing cells. Rosette formation was blocked by all tested CD4 specific
DARPins (200 nM, shown are D25.2 and D55.2) or by the CD4-specific mAb Q4120 but not by the control DARPin E3_5. One out of two representative
experiments is shown. (B) ELISpot assay to detect IFN-c production by activated T cells showed no interference of DARPin 55.2 with CD4
+ T cell
activation. The response of two donors against CMV or streptokinase/streptodornase (SKSD) antigen was tested without DARPin (gray) and with
nonspecific (blue) or CD4-specific DARPin (red) at 200 or 250 nM. One out of two independent experiments is depicted.
doi:10.1371/journal.ppat.1000109.g006
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proved them to be at least equally potent as the licensed entry
inhibitor T-20 (Enfuvirtide; [69,70]).
We used a truncated CD4 molecule, expressing only the apical
D1 and the adjacent D2 domain of CD4 as target in the ribosome
display selection, as these domains are involved in the interaction
with the virus and targeting of these regions by specific antibodies
have been shown to interfere with HIV infection [71–75]. D1
harbors the binding site for gp120 and interference is expected to
abrogate this interaction. The role of D2 in the infection process
appears to be more indirect, nevertheless important: the D2
specific antibody 5A8 blocks HIV infection efficiently and its
humanized derivative TNX-355 is now under clinical investigation
[69,76,77]. Notably, all tested DARPins selected against D1 and
D2 of CD4 in our screen inhibited HIV entry. The most obvious
concept of inhibiting HIV entry is blocking of the gp120 binding
site within the D1 domain of CD4 and thus direct interference
with viral attachment. Competition between virus and inhibitor
could likewise arise from binding to an epitope on D1 that is
different from the gp120 binding site, resulting in either
conformational changes or in stabilization of an incompatible
conformation of the entire domain.
Our screening strategy should enrich for DARPins specific for
D1, as competitive displacement from CD4 by gp120 was applied
in the final ribosome display rounds. It also has to be considered
that the D2 domain is probably less exposed in the tetrameric form
of CD4-IgG2 and therefore likely not as accessible for DARPin
binding during the screening. More detailed epitope mapping
using mouse human CD4 chimera showed that indeed all selected
DARPins bind to domain 1 of human CD4.
Notably though, we observed a partial competition between the
D2 specific mAb 5A8 and several of the DARPins for CD4 binding,
indicating that the epitopes of these DARPins may also involve
regions in D2 or are dependent on a D2 steered conformation.
We further found that engagement of CD4 by the DARPins
27.2, 29.2, 55.2, and 57.2 did not induce downregulation of CD4
(Figure 5D and data not shown), supporting the notion that direct
interference with gp120 binding to CD4 is their mode of action
(Figure 1B).
Although we developed the DARPin inhibitors with topical
application as a microbicide in mind, where comparatively low
systemic exposure is expected, it is nevertheless critical to carefully
assess their potential side effects on immune function. Despite
targeting a cellular receptor, we found the actions of the selected
CD4-specific DARPins tobe highly HIV specific. Noeffecton CD4-
independent virus entry was detected using murine leukemia virus.
Equally important, we did not observe effects on cell viability,
proliferation of T-cells, or activation of immature DC for the
individual DARPins probed in these assay systems, indicating that
these monovalent binders did not activate the receptor and initiated
downstream signaling events. Moreover, although DARPins can
interfere with the low affinity interaction between CD4 and MHC
class II which occurs in the absence of cognate TCR and peptide
(Figure 6A; [68]), DARPin treatment did not disturb activation of
specific memory T helper responses (Figure 6B). The latter supports
previous observations that CD4/MHC class II interaction is
tightened on TCR engagement [68,78], which may explain why
the inhibitory effect of the DARPin is overcome in this context.
The fact that targeting of CD4 by the high affinity DARPins
can occur without loss of CD4 T cell function and unwanted side
effects, holds great promise of their in vivo application. This is
further underlined by our finding that CD4-specific DARPins act
in synergy with several other HIV entry inhibitors directed to
different targets on the virus or host cell. The DARPin technology
is a relative young invention and the potential in vivo applications
of DARPins still await proof. This notwithstanding, our in vitro
analysis strongly suggests that DARPins have unique properties
that render them promising candidates for microbicide develop-
ment. Further assessment of their application as microbicides is
clearly feasible, particularly as we selected several molecules that
are specific for human and rhesus macaque CD4, which will allow
future study of their efficacy in the macaque infection model.
Accession numbers
The nucleotide and the amino acid sequences of the 12
DARPins described here were deposited in the EMBL Nucleotide
Sequence Data Base (www.ebi.ac.uk/embl) and are available
under the accession numbers AM997259–AM997270.
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Found at: doi:10.1371/journal.ppat.1000109.s001 (0.07 MB
DOC)
Figure S1 Repeat sequence motif of a DARPin repeat and X-
ray structure of a randomly selected member of the N3C DARPin
library, E3_5.
Figure 7. Human CD4 specific DARPins can crossreact with macaque CD4 and inhibit entry of SIV. (A) PBMC from rhesus macaques were
incubated with the indicated DARPins at 4uC, labeled with an anti-His-tag antibody and detected by flow cytometry. MFI (mean fluorescence
intensity) of DARPin staining on CD3
+ cells, corrected for the negative control is shown. Standard deviations are indicated and represent n=4
animals. (B) DARPin 25.2 potently inhibits entry of SIVmac239 in macaque PBMC. Shown are the IC90 values which were derived from neutralization
assays performed using DARPin 25.2 and the control E3_5 on PBMC from three different animals.
doi:10.1371/journal.ppat.1000109.g007
DARPins as Specific HIV Entry Inhibitors
PLoS Pathogens | www.plospathogens.org 11 July 2008 | Volume 4 | Issue 7 | e1000109Found at: doi:10.1371/journal.ppat.1000109.s002 (0.82 MB TIF)
Figure S2 Schematic representation of ribosome display selec-
tions.
Found at: doi:10.1371/journal.ppat.1000109.s003 (0.10 MB TIF)
Table S1 Inhibitory concentrations of 1st and 2nd series
DARPins.
Found at: doi:10.1371/journal.ppat.1000109.s004 (0.07 MB
DOC)
Acknowledgments
We thank Annette Oxenius and Manuela Rehr for help with assessment of
CD4 T helper cell activity, and Mike Scott and the Functional Genomics
Center Zurich for assistance with surface plasmon resonance studies.
Christian Zahnd, Michael Stumpp, and H. Kaspar Binz are acknowledged
for helpful discussions and Ingrid Nievergelt and Christine Vo ¨gtli for
administrative assistance. Additional thanks to Agegnehu Gettie and the
veterinary staff at TNPRC for providing the macaque blood samples. The
use of the Population Council’s Flow Cytometry Facility is gratefully
acknowledged. The following reagent was obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH: Human rIL-2 from Dr. Maurice Gately, Hoffmann - La Roche Inc.
[79].
Author Contributions
Conceived and designed the experiments: AS PR LB CRR AM SGT MF
MR PA AT. Performed the experiments: AS PR LB CRR AM SC SGT
MA. Analyzed the data: AS PR LB CRR AM SGT MR PA AT. Wrote the
paper: AS AT.
References
1. Berkley SF, Koff WC (2007) Scientific and policy challenges to development of
an AIDS vaccine. Lancet 370: 94–101.
2. (2007) AIDS Epidemic Update. December 2007. Joint United Nations
Programme on HIV/AIDS and World Health Organization.
3. Belyakov IM, Berzofsky JA (2004) Immunobiology of mucosal HIV infection
and the basis for development of a new generation of mucosal AIDS vaccines.
Immunity 20: 247–253.
4. Klasse PJ, Shattock R, Moore JP (2007) Antiretroviral drug-based microbicides
to prevent HIV-1 sexual transmission. Annu Rev Med 59: 455–71.
5. Stone A (2002) Microbicicdes: a new approach to preventing HIV and other
sexually transmitted infections. Nature Reviews Drug Discovery 1: 977–985.
6. Balzarini J, Van Damme L (2007) Microbicide drug candidates to prevent HIV
infection. Lancet 369: 787–797.
7. Hughes LM, Griffith R, Aitken RJ (2007) The search for a topical dual action
spermicide/microbicide. Curr Med Chem 14: 775–786.
8. Doncel GF (2006) Exploiting common targets in human fertilization and HIV
infection: development of novel contraceptive microbicides. Hum Reprod
Update 12: 103–117.
9. Check E (2007) Scientists rethink approach to HIV gels. Nature 446: 12.
10. Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, et al. (2005) In
vitro and in vivo: the story of nonoxynol 9. J Acquir Immune Defic Syndr 39:
1–8.
11. Ramjee G, Govinden R, Morar NS, Mbewu A (2007) South Africa’s Experience
of the Closure of the Cellulose Sulphate Microbicide Trial. PLoS Med 4: e235.
doi: 10.1371/journal.pmed.0040235.
12. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, et al. (2007)
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9
and inhibited by carrageenan. Nat Med 13: 857–861.
13. van de Wijgert JH, Braunstein SL, Morar NS, Jones HE, Madurai L, et al.
(2007) Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in
South Africa. J Acquir Immune Defic Syndr 46: 538–546.
14. D’Cruz OJ, Uckun FM (2006) Dawn of non-nucleoside inhibitor-based anti-
HIV microbicides. J Antimicrob Chemother 57: 411–423.
15. Fletcher P, Kiselyeva Y, Wallace G, Romano J, Griffin G, et al. (2005) The
nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immuno-
deficiency virus type 1 infection of human cervical tissue and dissemination by
migratory cells. J Virol 79: 11179–11186.
16. Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, et al. (2004)
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition
of CCR5. Science 306: 485–487.
17. Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, et al. (2005) Protection of
macaques from vaginal SHIV challenge by vaginally delivered inhibitors of
virus-cell fusion. Nature 438: 99–102.
18. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, et al. (2003) Prevention of
virus transmission to macaque monkeys by a vaginally applied monoclonal
antibody to HIV-1 gp120. Nat Med 9: 343–346.
19. Binz HK, Amstutz P, Plu ¨ckthun A (2005) Engineering novel binding proteins
from nonimmunoglobulin domains. Nat Biotechnol 23: 1257–1268.
20. Binz HK, Stumpp MT, Forrer P, Amstutz P, Plu ¨ckthun A (2003) Designing
repeat proteins: well-expressed, soluble and stable proteins from combinatorial
libraries of consensus ankyrin repeat proteins. J Mol Biol 332: 489–503.
21. Stumpp MT, Amstutz P (2007) DARPins: a true alternative to antibodies. Curr
Opin Drug Discov Devel 10: 153–159.
22. Amstutz P, Koch H, Binz HK, Deuber SA, Plu ¨ckthun A (2006) Rapid selection
of specific MAP kinase-binders from designed ankyrin repeat protein libraries.
Protein Eng Des Sel 19: 219–229.
23. Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, et al. (2004) High-affinity
binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol
22: 575–582.
24. Huber T, Steiner D, Ro ¨thlisberger D, Plu ¨ckthun A (2007) In vitro selection and
characterization of DARPins and Fab fragments for the co-crystallization of
membrane proteins: The Na(+)-citrate symporter CitS as an example. J Struct
Biol 159: 206–221.
25. Zahnd C, Pecorari F, Straumann N, Wyler E, Plu ¨ckthun A (2006) Selection and
characterization of Her2 binding-designed ankyrin repeat proteins. J Biol Chem
281: 35167–35175.
26. Amstutz P, Binz HK, Parizek P, Stumpp MT, Kohl A, et al. (2005) Intracellular
kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat
proteins. J Biol Chem.
27. Kawe M, Forrer P, Amstutz P, Plu ¨ckthun A (2006) Isolation of intracellular
proteinase inhibitors derived from designed ankyrin repeat proteins by genetic
screening. J Biol Chem 281: 40252–40263.
28. Schweizer A, Roschitzki-Voser H, Amstutz P, Briand C, Gulotti-Georgieva M,
et al. (2007) Inhibition of caspase-2 by a designed ankyrin repeat protein:
specificity, structure, and inhibition mechanism. Structure 15: 625–636.
29. Sennhauser G, Amstutz P, Briand C, Storchenegger O, Gru ¨tter MG (2006)
Drug export pathway of multidrug exporter AcrB revealed by DARPin
inhibitors. PLoS Biol 5: e7. doi:10.1371/journal.pbio.0050007.
30. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, et al. (1995)
Expression and characterization of CD4-IgG2, a novel heterotetramer that
neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 11:
533–539.
31. Hanes J, Plu ¨ckthun A (1997) In vitro selection and evolution of functional
proteins by using ribosome display. Proc Natl Acad Sci U S A 94: 4937–4942.
32. Zahnd C, Amstutz P, Plu ¨ckthun A (2007) Ribosome display: selecting and
evolving proteins in vitro that specifically bind to a target. Nat Methods 4:
269–279.
33. Zahnd C, Spinelli S, Luginbuhl B, Amstutz P, Cambillau C, et al. (2004)
Directed in vitro evolution and crystallographic analysis of a peptide-binding
single chain antibody fragment (scFv) with low picomolar affinity. J Biol Chem
279: 18870–18877.
34. Davis SJ, Schockmel GA, Somoza C, Buck DW, Healey DG, et al. (1992)
Antibody and HIV-1 gp120 recognition of CD4 undermines the concept of
mimicry between antibodies and receptors. Nature 358: 76–79.
35. Healey D, Dianda L, Moore JP, McDougal JS, Moore MJ, et al. (1990) Novel
anti-CD4 monoclonal antibodies separate human immunodeficiency virus
infection and fusion of CD4+ cells from virus binding. J Exp Med 172:
1233–1242.
36. Burkly LC, Olson D, Shapiro R, Winkler G, Rosa JJ, et al. (1992) Inhibition of
HIV infection by a novel CD4 domain 2-specific monoclonal antibody.
Dissecting the basis for its inhibitory effect on HIV-induced cell fusion.
J Immunol 149: 1779–1787.
37. Kohl A, Binz HK, Forrer P, Stumpp MT, Plu ¨ckthun A, et al. (2003) Designed to
be stable: crystal structure of a consensus ankyrin repeat protein. Proc Natl Acad
Sci U S A 100: 1700–1705.
38. Reichelt P, Schwarz C, Donzeau M (2006) Single step protocol to purify
recombinant proteins with low endotoxin contents. Protein Expr Purif 46:
483–488.
39. Furuta RA, Nishikawa M, Fujisawa J (2006) Real-time analysis of human
immunodeficiency virus type 1 Env-mediated membrane fusion by fluorescence
resonance energy transfer. Microbes Infect 8: 520–532.
40. Montefiori D (2004) Evaluating neutralizing antibodies against HIV, SIV, and
SHIV in luciferase reporter gene assays. New York: John Wiley and Sons, Inc.
pp 12.11.11–12.11.17.
41. Manrique A, Rusert P, Joos B, Fischer M, Kuster H, et al. (2007) In vivo and in
vitro escape from neutralizing antibodies 2G12, 2F5 and 4E10. J Virol 81:
8793–8808.
42. Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, et al. (2005) Virus isolates
during acute and chronic human immunodeficiency virus type 1 infection show
distinct patterns of sensitivity to entry inhibitors. J Virol 79: 8454–8469.
43. Rusert P, Fischer M, Joos B, Leemann C, Kuster H, et al. (2004) Quantification
of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol.
Virology 326: 113–129.
DARPins as Specific HIV Entry Inhibitors
PLoS Pathogens | www.plospathogens.org 12 July 2008 | Volume 4 | Issue 7 | e100010944. Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, et al. (2007) HIV-1
clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound
form of CCR5 for entry. Virology 361: 212–228.
45. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human
immunodeficiency virus type 1 env clones from acute and early subtype B
infections for standardized assessments of vaccine-elicited neutralizing antibod-
ies. J Virol 79: 10108–10125.
46. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, et al. (2006)
Genetic and neutralization properties of subtype C human immunodeficiency
virus type 1 molecular env clones from acute and early heterosexually acquired
infections in Southern Africa. J Virol 80: 11776–11790.
47. Berenbaum M (1978) A method for testing for synergy with any number of
agents. J Infect Dis 137: 122–130.
48. Loewe S (1928) Die quantitativen Probleme der Pharmakologie. Ergebn Physiol
28: 47–187.
49. Trkola A, Kuster H, Leemann C, Oxenius A, Fagard C, et al. (2004) Humoral
immunity to HIV-1: kinetics of antibody responses in chronic infection reflects
capacity of immune system to improve viral set point. Blood 104: 1784–1792.
50. Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, et al. (2005) Virus isolates
during acute and chronic human immunodeficiency virus type 1 infection show
distinct patterns of sensitivity to entry inhibitors. J Virol 79: 8454–8469.
51. Binley JM, Trkola A, Ketas T, Schiller D, Clas B, et al. (2000) The effect of
highly active antiretroviral therapy on binding and neutralizing antibody
responses to human immunodeficiency virus type 1 infection. J Infect Dis 182:
945–949.
52. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, et al. (2002) HIV
preferentially infects HIV-specific CD4+ T cells. Nature 417: 95–98.
53. Frank I, Stoessel H, Gettie A, Turville SG, Bess JW Jr, Lifson JD, Sivin I,
Romani N, Robbiani M (2008) A fusion inhibitor prevents dendritic cell (DC)
spread of immunodeficiency viruses but not DC activation of virus-specific T
cells. J Virol, in press, Epub ahead of print.
54. Lyons AB, Parish CR (1994) Determination of lymphocyte division by flow
cytometry. J Immunol Methods 171: 131–137.
55. Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ (2001) Development and
validation of a gamma interferon ELISPOT assay for quantitation of cellular
immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 8:
871–879.
56. Sakihama T, Smolyar A, Reinherz EL (1995) Oligomerization of CD4 is
required for stable binding to class II major histocompatibility complex proteins
but not for interaction with human immunodeficiency virus gp120. Proc Natl
Acad Sci U S A 92: 6444–6448.
57. Clayton LK, Hussey RE, Steinbrich R, Ramachandran H, Husain Y, et al.
(1988) Substitution of murine for human CD4 residues identifies amino acids
critical for HIV-gp120 binding. Nature 335: 363–366.
58. Montefiori D (2004) Evaluating neutralizing antibodies against HIV, SIV, and
SHIV in luciferase reporter gene assays. In: Coligan JEKA, Margulies DH,
Shevach EM, Strober W, eds. Current protocols in immunology. New York:
John Wiley and Sons. pp 12.11.11–12.11.17.
59. Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, et al. (2007) A
designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol
369: 1015–1028.
60. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, et al. (1998)
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor
of gp41-mediated virus entry. NatMed 4: 1302–1307.
61. Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, et al. (2003)
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North
and South America. N Engl J Med 348: 2175–2185.
62. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, et al. (2003) Efficacy of
enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and
Australia. N Engl J Med 348: 2186–2195.
63. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, et al. (1994) Efficient
neutralization of primary isolates of HIV-1 by a recombinant human
monoclonal antibody. Science 266: 1024–1027.
64. Purtscher M, Trkola A, Grassauer A, Schulz PM, Klima A, et al. (1996)
Restricted antigenic variability of the epitope recognized by the neutralizing
gp41 antibody 2F5. Aids 10: 587–593.
65. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, et al. (2001) A
potent cross-clade neutralizing human monoclonal antibody against a novel
epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum
Retroviruses 17: 1757–1765.
66. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. (1996) Human
monoclonal antibody 2G12 defines a distinctive neutralization epitope on the
gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70:
1100–1108.
67. Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, et al. (1999)
Differential inhibition of human immunodeficiency virus type 1 fusion, gp120
binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol
73: 4145–4155.
68. Xiong Y, Kern P, Chang H, Reinherz E (2001) T Cell Receptor Binding to a
pMHCII Ligand Is Kinetically Distinct from and Independent of CD4. J Biol
Chem 276: 5659–5667.
69. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, et al. (2004)
Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in
patients infected with HIV type 1. J Infect Dis 189: 286–291.
70. Este JA, Telenti A (2007) HIV entry inhibitors. Lancet 370: 81–88.
71. Healey DG, Dianda L, Buck D, Schroeder K, Truneh A, et al. (1991) A highly
selected panel of anti-CD4 antibodies fails to induce anti-idiotypic antisera
mediating human immunodeficiency virus neutralization. Eur J Immunol 21:
1491–1498.
72. Matthias LJ, Yam PT, Jiang XM, Vandegraaff N, Li P, et al. (2002) Disulfide
exchange in domain 2 of CD4 is required for entry of HIV-1. Nat Immunol 3:
727–732.
73. Moore JP, McKeating JA, Huang YX, Ashkenazi A, Ho DD (1992) Virions of
primary human immunodeficiency virus type 1 isolates resistant to soluble CD4
(sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention
from sCD4-sensitive isolates. J Virol 66: 235–243.
74. Moore JP, Sattentau QJ, Klasse PJ, Burkly LC (1992) A monoclonal antibody to
CD4 domain 2 blocks soluble CD4-induced conformational changes in the
envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and
HIV-1 infection of CD4+ cells. J Virol 66: 4784–4793.
75. Truneh A, Buck D, Cassatt DR, Juszczak R, Kassis S, et al. (1991) A region in
domain 1 of CD4 distinct from the primary gp120 binding site is involved in
HIV infection and virus-mediated fusion. J Biol Chem 266: 5942–5948.
76. Boon L, Holland B, Gordon W, Liu P, Shiau F, et al. (2002) Development of
anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment
in non-human primates. Toxicology 172: 191–203.
77. Reimann KA, Lin W, Bixler S, Browning B, Ehrenfels BN, et al. (1997) A
humanized form of a CD4-specific monoclonal antibody exhibits decreased
antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its
unique biological and antiviral properties. AIDS Res Hum Retroviruses 13:
933–943.
78. Hamad AR, O’Herrin SM, Lebowitz MS, Srikrishnan A, Bieler J, et al. (1998)
Potent T cell activation with dimeric peptide-major histocompatibility complex
class II ligand: the role of CD4 coreceptor. J Exp Med 188: 1633–1640.
79. Lahm HW, Stein S (1985) Characterization of recombinant human interleukin-2
with micromethods. J Chromatogr 326: 357–361.
DARPins as Specific HIV Entry Inhibitors
PLoS Pathogens | www.plospathogens.org 13 July 2008 | Volume 4 | Issue 7 | e1000109